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Introduction
HIV testing algorithms include a supplemental assay to
confirm and differentiate HIV-1 and HIV-2 on repeated
reactive samples by a 4th generation EIA screening test
(EIA). In this study we evaluate the recently CE-marked
Bio-Rad Geenius HIV1/2 (Geenius) confirmatory assay, a
single use immunochromatographic test, in comparison
with the MP Diagnostic HIV Blot 2.2 (WB).
Methods
A total of 161 serum samples were tested by Geenius test:
72 nonreactive samples by EIA (Liaison XL Murex and/or
VIDAS bioMérieux), 8 indeterminate samples by WB con-
firmed negative after follow up, 5 low reactive samples by
EIA negative by WB and confirmed negative after follow
up, 44 HIV-1 reactive samples by EIA and WB, 5 HIV-2
reactive samples, 1 HIV-1/HIV-2 co-infection sample,
15 HIV-1 non-B subtype samples (8 CRF02, 1 CRF01,
1 CRF11, 1 CRF15, 2 subtype G, 1 subtype F1, 1 subtype
C) and 11 confirmed HIV-1 early seroconversion samples.
The samples were tested according to the manufacturer’s
guidelines. Geenius cassettes were read and interpreted by
an automated reader utilizing a proprietary algorithm. The
diagnostic performance and the quality management of
the test were analyzed.
Results
Overall sensitivity for Geenius assay was 92%. Five of 11
early seroconversion samples were tested positive, 4
negative and 2 indeterminate. The overall sensitivity of
WB was 88%. After excluding early seroconversion sam-
ples, the sensitivity reaches 100% for both assays. All
HIV-1 non-B subtype samples were tested positive. The
ability to differentiate HIV-1 and HIV-2 was as follow: 2
out of the 5 HIV-2 reactive samples were tested positive
HIV-2, 2 positive HIV-2 with HIV-1 cross reaction, and
1 HIV positive untypable. The co-infection HIV-1/HIV-2
sample was tested HIV positive untypable. The overall
specificity for the Geenius assay was 96%. All 5 low reac-
tive samples by EIA, negative by WB were tested negative
by Geenius. Two out of the 8 indeterminate samples by
WB confirmed negative were tested indeterminate and
one invalid, the other 6 were negative. After excluding
these last 13 samples, the specificity of Geenius assay
reached 100%. In comparison with WB, the Geenius assay
is markedly less time consuming (<30 minutes), allows full
traceability, automatic reading and interpretation.
Conclusions
The Bio-Rad Geenius HIV1/2 confirmatory system
represents a reliable alternative to other confirmatory
assays in HIV testing algorithms and provides clear
improvement in quality management.
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